Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00266565

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions Churg-Strauss Syndrome Eosinophilic Esophagitis Eosinophilic Gastroenteritis Hypereosinophilic Syndromes

Interventions Mepolizumab

Updated 7 times since 2017 Last updated: Jul 27, 2020 Started: Dec 31, 2001 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Churg-Strauss Syndrome and Eosinophilic Esophagitis and is currently completed. Children's Hospital Medical Center, Cincinnati leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Aug 2020 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Hospital Medical Center, Cincinnati

Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States